Group 1 - The core viewpoint of the article highlights the successful progress of Huazhan Biotechnology's listing process, with its unique PDGF drug pipeline and broad market prospects attracting significant industry attention [1] - Huazhan Biotechnology, established in 2012, has developed ten candidate products covering 14 types of wound healing indications, with a competitive advantage in its core product matrix [1] - Pro-101-1 is noted as the fastest PDGF candidate drug for treating burns in clinical development in China, while Pro-101-2 targets diabetic foot ulcers, addressing a significant market gap and providing hope for patients [1] Group 2 - The increasing prevalence of diabetes, driven by an aging population and unhealthy lifestyles, is leading to a rise in diabetic foot ulcer cases, with a concerning trend of younger patients being affected [1] - According to a Frost & Sullivan report, a diabetic patient faces amputation risk every 20 seconds globally, with a mortality rate of 22% among amputees, indicating a pressing clinical treatment demand [1] - Huazhan Biotechnology's PDGF core products target hard-to-heal wounds, with a substantial market size in the wound healing sector and potential access to a trillion-level consumer healthcare market, showcasing significant commercialization potential and social impact [1]

7月16日，贵州百灵官微消息，由贵州百灵申办、南通大学附属医院顾云娟教授担任主要研究者的"糖宁 通络片联合糖宁通络乳膏对2型糖尿病足溃疡的临床疗效与安全性研究"成果论文，在中国科技核心期刊 《湖南师范大学学报（医学版）》正式发表。研究结果表明：糖宁通络片及糖宁通络乳膏均能显著促进 糖尿病足溃疡创面愈合，且二者联合治疗的长期效果更优，能够增强局部免疫力、抑制细菌生长，并降 低感染的风险，改善了糖尿病足患者的临床预后，具有较高的临床应用价值。 ...